Fig. 1
From: RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?
Views of ambiguous lesions selected at baseline evaluation (derived from RECIST blinded double-reading central review database). a measurable adrenal nodule believed to be a metastatic lesion from the primary lung cancer (follow-up: revealed to be a benign incidentaloma); b 10 mm nodule with ground glass in a context of metastatic colon (follow-up: revealed to be malignant and responded like the rest of the TLs); c non-measurable well-defined lung micro-nodule in a context of head-neck cancer follow-up (follow-up: revealed to be stable and most probably benign); d non-measurable supra-centimetric mediastinal lymph node in a context of colon cancer (follow-up: revealed to be stable supra-centimetric); e low conspicuity of a blastic bone lesion (follow-up: revealed to be a metastatic lesion confirmed by sclerotic healing changes); f hypervascular centimetric nodule in the liver in the context of metastatic colon cancer (follow-up: revealed to be stable and probably unrelated to the cancer)